Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.

Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J.

Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.

2.

A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.

Stubdal H, Perin N, Lemmon M, Holman P, Bauzon M, Potter PM, Danks MK, Fattaey A, Dubensky T, Johnson L.

Cancer Res. 2003 Oct 15;63(20):6900-8.

3.

Developing novel oncolytic adenoviruses through bioselection.

Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, Watanabe J, Holt J, Lee V, Dubensky T, Fattaey A, Hermiston T, Balmain A, Shen Y.

J Virol. 2003 Feb;77(4):2640-50.

4.

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.

Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A.

Cancer Cell. 2002 May;1(4):325-37.

5.

Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein.

Shen Y, Kitzes G, Nye JA, Fattaey A, Hermiston T.

J Virol. 2001 May;75(9):4297-307.

6.

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD.

J Biol Chem. 2001 May 18;276(20):16617-23. Epub 2001 Feb 6.

7.

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E.

J Med Chem. 2000 Nov 30;43(24):4606-16.

PMID:
11101352
8.

CDK inhibition and cancer therapy.

Garrett MD, Fattaey A.

Curr Opin Genet Dev. 1999 Feb;9(1):104-11. Review.

PMID:
10072351
9.

Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity.

Booher RN, Holman PS, Fattaey A.

J Biol Chem. 1997 Aug 29;272(35):22300-6.

10.

New functional activities for the p21 family of CDK inhibitors.

LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E.

Genes Dev. 1997 Apr 1;11(7):847-62.

11.

Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14.

Fattaey A, Booher RN.

Prog Cell Cycle Res. 1997;3:233-40. Review.

PMID:
9552418
12.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F.

Science. 1996 Oct 18;274(5286):373-6.

PMID:
8832876
13.

Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.

Vidal M, Brachmann RK, Fattaey A, Harlow E, Boeke JD.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10315-20.

14.

Direct interaction of human TFIID with the HIV-1 transactivator tat.

Kashanchi F, Piras G, Radonovich MF, Duvall JF, Fattaey A, Chiang CM, Roeder RG, Brady JN.

Nature. 1994 Jan 20;367(6460):295-9.

PMID:
8121496
15.
16.

Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1.

Dyson N, Dembski M, Fattaey A, Ngwu C, Ewen M, Helin K.

J Virol. 1993 Dec;67(12):7641-7.

17.

Characterization of the retinoblastoma binding proteins RBP1 and RBP2.

Fattaey AR, Helin K, Dembski MS, Dyson N, Harlow E, Vuocolo GA, Hanobik MG, Haskell KM, Oliff A, Defeo-Jones D, et al.

Oncogene. 1993 Nov;8(11):3149-56.

PMID:
8414517
18.

Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein.

Helin K, Harlow E, Fattaey A.

Mol Cell Biol. 1993 Oct;13(10):6501-8.

19.

Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation.

Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, Harlow E.

Genes Dev. 1993 Oct;7(10):1850-61.

20.

Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E.

Genes Dev. 1993 Jul;7(7A):1111-25.

21.

Transcriptional inhibition by the retinoblastoma protein.

Fattaey A, Helin K, Harlow E.

Philos Trans R Soc Lond B Biol Sci. 1993 Jun 29;340(1293):333-6.

PMID:
8103936
22.

A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F.

Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A.

Cell. 1992 Jul 24;70(2):337-50.

PMID:
1638634
23.
24.

Supplemental Content

Loading ...
Support Center